A key concern with long-term use of vitamin K antagonists is harm resulting from hemorrhagic complications. Long-term use of low-molecular-weight heparin, although administered subcutaneously, may be a viable option. There is a need for an effective and safe alternative to therapy with vitamin K antagonists in a broad spectrum of patients with venous thrombosis.
Frank and colleagues, and synopses of the other three winning achievements are available at cmaj.ca. Devereaux and colleagues, the essay by Dr.
Hull describes his work in treatments for venous thrombosis in the following essay. See related articles by Kelsall at by Frank and colleagues at and by Devereaux and colleagues at Russell Hull, the POISE-1 investigators, and Cyril Frank and colleagues for the Alberta Bone and Joint Health Institute are the highest-ranking winners of the 2009–2010 CIHR/ CMAJ competition for the Top Achievements in Health Research.
0 kommentar(er)
